ALS ONE's 7th Annual ALS ONE Research Symposium, held November 13, 14, and 15, 2024, hosted by our research team: Dr’s Merit Cudkowicz, MD, MSc of MGH, Robert H Brown, Jr. MD, DPhil of UMass Medical School, James Berry, MD, MPH of MGH, Sabrina Paganoni, MD, PhD of MGH, and Fernando Vieira, MD of ALS TDI, and in collaboration with Indu Navar and EverythingALS for Day 3's Neurotechnology Day. The conference had over 900 registered guests from 37 countries, including researchers, scientists, and members of the ALS community from around the world, convening virtually for 3 days (Day 1: Keynote Speakers, Day 2: ALS Industry Day, Day 3: Neurotechnology Day), of sharing critical research that is underway across the globe to help uncover therapeutic options leading to an ultimate cure for Amyotrophic Lateral Sclerosis (ALS). Recordings were made of the presentations which we are/were approved to share.

IN THIS VIDEO:
Symposium Segment (Day 2): ALS Industry Day Presentations

Title: A Phase 1/2, Multicenter Study to Evaluate the Safety, Tolerability, and Exploratory Efficacy of Intrathecally Administered Gene Therapy AMT-162 in Patients with SOD1 Amyotrophic Lateral Sclerosis (SOD1-ALS).

Speaker: Dr. Brenda Vicenzi. Executive Director, Clinical Development at uniQure.

Moderator: Dr. Fernando Vieira, MD.

To learn more about this year's Symposium, visit: [ Ссылка ]

ALS ONE is a 501c3 non-profit organization focused entirely on ALS research and care. To learn more about ALS ONE or to support our mission, visit: www.alsone.org.

свернуть